Bio-markers of immuno-oncology

Abstract

Since its inception until the rapid advancements, the immuno-oncology (I-O) landscape has undergone significant modifications. Thousands of possible I-O medicines and therapy combinations are being tested in clinical trials as part of the current drug development pipeline. Suppose these assets are to be developed effectively and successfully. In that case, it is necessary to invest in and use the proper techniques and technology to speed up the transition from preclinical evaluation to clinical development. These tools, which include suitable preclinical models, pharmacodynamics-related biomarkers, prediction and monitoring capabilities, and developing clinical trial designs, enable quick and effective evaluation during the development process.The possibility of new findings and insights in each of these three areas to further address the clinical care needs of patients with cancer.These tools include. 1. Appropriate preclinical models, 2. Biomarkers of pharmacodynamics, predictive and monitoring utility, and. 3. Evolving clinical trial designs allow rapid and efficient evaluation during the development process.This article provides an overview of how novel discoveries and insights into each of these three areas have the potential further to address the clinical management needs of patients with cancer.